XML 60 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ORGANIZATION AND NATURE OF THE BUSINESS (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Jan. 06, 2023
Jan. 23, 2024
Jun. 30, 2023
Jun. 15, 2023
Apr. 24, 2023
Mar. 17, 2023
Feb. 28, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Stockholders' equity               $ 36,043,028 $ 39,284,295 $ 4,379,463
Accumulated deficit               (91,644,233) (66,232,813)  
Working capital               12,285,310    
Revenue               53,376,874 50,347,652  
Net loss               (18,542,654) (13,830,371)  
Net cash used in operations               14,998,919    
Repayment of outstanding Facility               1,908,195    
Building Acquision [Member]                    
Cash $ 3,950,000       $ 1,054,872          
Equity method investment aggregate cost $ 2,000,020                  
Greece [Member]                    
Revenue               50,526,307 $ 49,812,839  
Cash       $ 109,330            
Intangible assets       425,411            
Issuable stock amount       $ 316,081            
Shares issued       99,710            
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]                    
Cash     $ 873,600              
Issuable stock amount     $ 138,667         $ 138,667    
Shares issued     46,377              
Asset acquision             $ 5,469,787      
Secured Promissory Note             $ 4,457,520      
Zip Doctor Inc [Member]                    
Cash           $ 150,000        
Payment in fees           8,788        
Intangible assets           $ 158,788        
Cloudscreen [Member]                    
Cash   $ 317,880                
Total purchase price amount   $ 637,080                
Shares of common stock issued   280,000                
Shares of common fair value   $ 319,200                
Asset acquisition   $ 637,080